Limited data on the clinical management of drug-drug interactions between triazoles and Cystic Fibrosis transmembrane conductance regulator (CFTR) modulators are available. We retrospectively evaluated azole target attainment and dose adaptations in patients from two Dutch CF centres concomitantly receiving triazoles and CFTR modulators. In total, 21 patients with 59 triazole trough concentrations were evaluated. Subtherapeutic concentrations were frequently observed, especially for itraconazole and voriconazole. Of the investigated antifungal agents, posaconazole appears the most preferable option. Our results emphasize the importance of adequate management of this interaction and underpin the added value of therapeutic drug monitoring of triazoles in this population.

中文翻译：

---

在现实生活队列中评估三唑类抗真菌药和囊性纤维化跨膜电导调节剂之间的药物相互作用

关于三唑类药物与囊性纤维化跨膜电导调节剂 (CFTR) 调节剂之间药物相互作用的临床管理数据有限。我们回顾性评估了来自两个荷兰 CF 中心同时接受三唑和 CFTR 调节剂治疗的患者的唑类目标达到情况和剂量适应情况。总共对 21 名患者的 59 种三唑谷浓度进行了评估。经常观察到低于治疗浓度，特别是伊曲康唑和伏立康唑。在所研究的抗真菌药物中，泊沙康唑似乎是最优选的选择。我们的结果强调了充分管理这种相互作用的重要性，并支持了该人群中三唑治疗药物监测的附加值。